Literature DB >> 33344913

Docking Prediction of Amantadine in the Receptor Binding Domain of Spike Protein of SARS-CoV-2.

Abdul Mannan Baig1, Areeba Khaleeq1, Hira Syeda2.   

Abstract

Amantadine has recently been shown to improve patients with COVID-19. In addition to its known mechanism of actions, we performed docking prediction of this drug on the receptor-binding domain of severe acute respiratory syndrome coronavirus 2, SARS-CoV-2. We hypothesize that such interaction may possibly have contributed a role in the clinical improvements reported.
© 2020 American Chemical Society.

Entities:  

Year:  2020        PMID： 33344913      PMCID： PMC7737314          DOI： 10.1021/acsptsci.0c00172

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN： 2575-9108


  6 in total

1.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor.

Authors:  Jun Lan; Jiwan Ge; Jinfang Yu; Sisi Shan; Huan Zhou; Shilong Fan; Qi Zhang; Xuanling Shi; Qisheng Wang; Linqi Zhang; Xinquan Wang
Journal:  Nature       Date:  2020-03-30       Impact factor: 49.962

2.  DrugBank 4.0: shedding new light on drug metabolism.

Authors:  Vivian Law; Craig Knox; Yannick Djoumbou; Tim Jewison; An Chi Guo; Yifeng Liu; Adam Maciejewski; David Arndt; Michael Wilson; Vanessa Neveu; Alexandra Tang; Geraldine Gabriel; Carol Ly; Sakina Adamjee; Zerihun T Dame; Beomsoo Han; You Zhou; David S Wishart
Journal:  Nucleic Acids Res       Date:  2013-11-06       Impact factor: 16.971

3.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.

Authors:  Yuanyuan Zhang; Yaning Li; Renhong Yan; Lu Xia; Yingying Guo; Qiang Zhou
Journal:  Science       Date:  2020-03-04       Impact factor: 47.728

4.  Observational study of people infected with SARS-Cov-2, treated with amantadine.

Authors:  Gonzalo Emiliano Aranda-Abreu; José D Aranda-Martínez; Ramiro Araújo; María Elena Hernández-Aguilar; Deissy Herrera-Covarrubias; Fausto Rojas-Durán
Journal:  Pharmacol Rep       Date:  2020-10-10       Impact factor: 3.024

5.  Elucidation of cellular targets and exploitation of the receptor-binding domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.

Authors:  Abdul Mannan Baig; Areeba Khaleeq; Hira Syeda
Journal:  J Med Virol       Date:  2020-07-17       Impact factor: 20.693

6.  Structural basis of receptor recognition by SARS-CoV-2.

Authors:  Jian Shang; Gang Ye; Ke Shi; Yushun Wan; Chuming Luo; Hideki Aihara; Qibin Geng; Ashley Auerbach; Fang Li
Journal:  Nature       Date:  2020-03-30       Impact factor: 49.962
  6 in total
  9 in total

Review 1.  COVID-19 and Parkinson's Disease: Possible Links in Pathology and Therapeutics.

Authors:  Shubhangini Tiwari; Neelam Yadav; Sarika Singh
Journal:  Neurotox Res       Date:  2022-07-13       Impact factor: 3.978

2.  Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.

Authors:  Albert Cortés-Borra; Gonzalo Emiliano Aranda-Abreu
Journal:  Pharmacol Rep       Date:  2021-02-18       Impact factor: 3.024

3.  Amantadine-assembled nanostimulator enhances dimeric RBD antigen-elicited cross-neutralization against SARS-CoV-2 strains.

Authors:  Ye Zhang; Ruixin Wang; Chunyan He; Yu-Fang Zhang; Zhongrui Luo; Jia Luo; Sisi Chen; Yu Jin; Bowen Xie; Ye Liu
Journal:  Nano Today       Date:  2022-01-12       Impact factor: 18.962

4.  Amantadine-Induced Cardiac Arrest in a Patient With COVID-19.

Authors:  Bibek Bakhati; Victoria M Sibi; Armugam P Mekala; Joshua A Ronen; Sai S Mungara
Journal:  Cureus       Date:  2022-01-17

5.  The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design.

Authors:  Konrad Rejdak; Piotr Fiedor; Robert Bonek; Aleksander Goch; Agnieszka Gala-Błądzińska; Waldemar Chełstowski; Jacek Łukasiak; Sławomir Kiciak; Piotr Dąbrowski; Mateusz Dec; Zbigniew J Król; Ewa Papuć; Adriana Zasybska; Agnieszka Segiet; Paweł Grieb
Journal:  Contemp Clin Trials       Date:  2022-04-04       Impact factor: 2.261

6.  Underlying Causes and Treatment Modalities for Neurological Deficits in COVID-19 and Long-COVID.

Authors:  Abdul Mannan Baig; Nigel H Greig; Joachim Gerlach; Prakash Salunke; Mark Fabrowski; Valentina Viduto; Tazeen Ali
Journal:  ACS Chem Neurosci       Date:  2022-10-03       Impact factor: 5.780

Review 7.  Potential for the Repurposing of Adamantane Antivirals for COVID-19.

Authors:  Roger F Butterworth
Journal:  Drugs R D       Date:  2021-06-21

8.  In silico Screening of Natural Phytocompounds Towards Identification of Potential Lead Compounds to Treat COVID-19.

Authors:  Muthumanickam Sankar; Balajee Ramachandran; Boomi Pandi; Nachiappan Mutharasappan; Vidhyavathi Ramasamy; Poorani Gurumallesh Prabu; Gowrishankar Shanmugaraj; Yao Wang; Brintha Muniyandai; Subaskumar Rathinasamy; Balakumar Chandrasekaran; Mohammad F Bayan; Jeyakanthan Jeyaraman; Gurumallesh Prabu Halliah; Solomon King Ebenezer
Journal:  Front Mol Biosci       Date:  2021-07-05

9.  Amantadine Inhibits SARS-CoV-2 In Vitro.

Authors:  Klaus Fink; Andreas Nitsche; Markus Neumann; Marica Grossegesse; Karl-Heinz Eisele; Wojciech Danysz
Journal:  Viruses       Date:  2021-03-24       Impact factor: 5.048
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.